Prof Jeroen Dekervel, gastrological oncologist at University Hospital Leuven and Dr Javier Carrasco, Grand Hospital de Charleroi, summarizes the poster presented.
R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patiens with locally advanced rectal cancer (LARC).
The coadministration of immunotherapy employing atezolizumab alongside radio-chemotherapy in locally advanced rectal cancer (LARC) patients within the neoadjuvant context exhibits potential for heightened efficacy. The presented data delineate a favourable safety profile that does not compromise tumour surgical interventions. The attainment of pathological complete response (pCR) underscores the effectiveness of this therapeutic regimen. Concurrently, investigations into the relationship between efficacy and biomarkers possessing predictive potential are underway.
With the educational support of:
 |
 |